INCREASED VASCULAR SELECTIVITY AND PROLONGED PHARMACOLOGICAL EFFICACY OF THE L-TYPE Ca super(2+) CHANNEL ANTAGONIST LERCANIDIPINE IN HUMAN CARDIOVASCULAR TISSUE
1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic...
Saved in:
Published in | Clinical and experimental pharmacology & physiology Vol. 32; no. 9; pp. 708 - 713 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.09.2005
|
Online Access | Get full text |
Cover
Loading…
Abstract | 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic heart transplants) or in isolated right atrial trabeculae and isolated vessel preparations of arteria mammaria obtained from patients undergoing aortocoronary bypass operation. 2. The obtained rank order for the L-type Ca super(2+) channel affinity in human tissue was LER > NIF greater than or equal to AML. Lercanidipine had the lowest negative inotropic efficacy (1 mu mol-L LER: 60.3% basal < AML: 79.1% basal < NIF: 92.4 basal) and potency (IC sub(50) NIF: 3.5 nmol-L < AML: 48 nmol-L < Ler: 127 nmol-L) in right atrial trabeculae. 3. The vasorelaxant potency of LER (IC sub(50) 0.5 nmol-L) and AML (IC sub(50) 0.8 nmol-L) was similar and significantly increased compared with that of NIF (IC sub(50) 5.9 nmol-L) in arteria mammaria preparations of the very same patients. 4. The following rank order was obtained for vasoselectivity: LER (260) < AML (60) < NIF (0.6). 5. The pharmacological effects of LER and AML were still present 2 h after drug washout. 3. Lercanidipine is characterized by a high vasoselectivity and a prolonged interaction with the L-type calcium channel in human cardiovascular tissue This may be advantageous, especially in the treatment of patients with arterial hypertension. |
---|---|
AbstractList | 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic heart transplants) or in isolated right atrial trabeculae and isolated vessel preparations of arteria mammaria obtained from patients undergoing aortocoronary bypass operation. 2. The obtained rank order for the L-type Ca super(2+) channel affinity in human tissue was LER > NIF greater than or equal to AML. Lercanidipine had the lowest negative inotropic efficacy (1 mu mol-L LER: 60.3% basal < AML: 79.1% basal < NIF: 92.4 basal) and potency (IC sub(50) NIF: 3.5 nmol-L < AML: 48 nmol-L < Ler: 127 nmol-L) in right atrial trabeculae. 3. The vasorelaxant potency of LER (IC sub(50) 0.5 nmol-L) and AML (IC sub(50) 0.8 nmol-L) was similar and significantly increased compared with that of NIF (IC sub(50) 5.9 nmol-L) in arteria mammaria preparations of the very same patients. 4. The following rank order was obtained for vasoselectivity: LER (260) < AML (60) < NIF (0.6). 5. The pharmacological effects of LER and AML were still present 2 h after drug washout. 3. Lercanidipine is characterized by a high vasoselectivity and a prolonged interaction with the L-type calcium channel in human cardiovascular tissue This may be advantageous, especially in the treatment of patients with arterial hypertension. |
Author | Geissler, Hans-Joachim Tossios, Paschalios Brixius, Klara Schwinger, Robert Hg Hekmat, Khosro Mehlhorn, Uwe Gross, Thomas |
Author_xml | – sequence: 1 givenname: Klara surname: Brixius fullname: Brixius, Klara – sequence: 2 givenname: Thomas surname: Gross fullname: Gross, Thomas – sequence: 3 givenname: Paschalios surname: Tossios fullname: Tossios, Paschalios – sequence: 4 givenname: Hans-Joachim surname: Geissler fullname: Geissler, Hans-Joachim – sequence: 5 givenname: Uwe surname: Mehlhorn fullname: Mehlhorn, Uwe – sequence: 6 givenname: Robert surname: Schwinger middlename: Hg fullname: Schwinger, Robert Hg – sequence: 7 givenname: Khosro surname: Hekmat fullname: Hekmat, Khosro |
BookMark | eNqNjt1KwzAcxYNMsFPf4X8lirQm_dp2GdK0DWRpadJBr0aRCo7azcWCj-OjmgvZtefmcDg_DmeJFtNxGhACggPi9HIISBxjn6RrEoQYJwGOwzQJvq-QdykWyMMRTnyyXuEbtLT2gB2J08hDP0KxhlPNM9hRzVpJG9BccmbETpgOqMqgbipZqcIhdUmbLWUuFoJRCTzPnbMOqhxMyUH6pqs5sB7sfBrOj-HzE7CSKsWlWzK0qJTQBiRvGFUiE7VQHISCst1SBYw2maguN4zQuuV36PqtH-1w_-e36CHnhpX-6Xz8nAf7tf94t6_DOPbTcJztnqziaJMmm-jf4C-TFlph |
ContentType | Journal Article |
DBID | 7QP |
DOI | 10.1111/j.1440-1681.2005.04265.x |
DatabaseName | Calcium & Calcified Tissue Abstracts |
DatabaseTitle | Calcium & Calcified Tissue Abstracts |
DatabaseTitleList | Calcium & Calcified Tissue Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1440-1681 |
EndPage | 713 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29B 2QV 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 7QP 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DXH EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KTM LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT |
ID | FETCH-proquest_miscellaneous_174396593 |
ISSN | 0305-1870 |
IngestDate | Sat Aug 17 03:11:09 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_miscellaneous_174396593 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-2 |
PQID | 17439659 |
PQPubID | 23462 |
ParticipantIDs | proquest_miscellaneous_17439659 |
PublicationCentury | 2000 |
PublicationDate | 20050901 |
PublicationDateYYYYMMDD | 2005-09-01 |
PublicationDate_xml | – month: 09 year: 2005 text: 20050901 day: 01 |
PublicationDecade | 2000 |
PublicationTitle | Clinical and experimental pharmacology & physiology |
PublicationYear | 2005 |
SSID | ssj0005063 |
Score | 3.537548 |
Snippet | 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 708 |
Title | INCREASED VASCULAR SELECTIVITY AND PROLONGED PHARMACOLOGICAL EFFICACY OF THE L-TYPE Ca super(2+) CHANNEL ANTAGONIST LERCANIDIPINE IN HUMAN CARDIOVASCULAR TISSUE |
URI | https://search.proquest.com/docview/17439659 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9pAEIBXNL30UrVJq747hxa1chwRjI193CwGOzW2ZS9ROCEDRuIQiAKWmv6a_rj-kI7X7zZq2l4MMtYamE-zM-N5EPJhqSsaWgW6nFqjMu5QimxoRldWjNO5vlRXnZ7ozj92NWvSO79UL1utH7WspWQ_P1l8u7Ou5H-kiudQrmmV7D9ItlwUT-B7lC8eUcJ4_CsZo0cemDQ0B9IFDdnEoYEUmo7JuH1h86noHOUHnuO5I7zEt2gwpqycfoAWKr6yaZH348h86psSi6Rdcp0KUu9-7J6lUQNmUdc1HVyP05Hn2iGXHDNg1LUHtm-76dR6yZqMqSsxGgxsr_wy3A7DiVm3f1lRiJnG6xvTBa6rHtpZEo-IuTSC_mc366_rRID3BR3yckMZFaPfa9lOInCeZvjmgwjQiUePY1t-OIqRuLwK0sLtWj5PK8vWV40oiFqmeZXVX2lHVT0bQnISZ8pcPLfWspEwhbavoqlJkc-eqe5-R69ZAf2sQvYPG0y-dh6WQ0NHLRJP6z29XW82nDjOjJuX_AF52EV1KJIJgqrJmZrP-yt-QTPf7M77_GY4CGuIPyGPczcGaMbkU9KKN4fkiG6i_fbqFtrgl8I7JG0_E-3tMfCq2m93LC6rhH5Evpc8Q4EQ1HgG5BlKnuEXnqHgGbwhIM-Q8QwsAsHzp670GXKSoSIZGiSD7YIgGZokQ0byM9IempxZcvG3zFBLpo--ok28TXYz4XdrqqE8Jweb7SZ-QWC-6MWd2FB6htrvLRdKFPcjY66tUEl1FqfR6iV5f89ir-694jV5VMH6hhzsb5L4LRqx-_k7wcBPOWGLzg |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Wiley-Blackwell |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=INCREASED+VASCULAR+SELECTIVITY+AND+PROLONGED+PHARMACOLOGICAL+EFFICACY+OF+THE+L-TYPE+Ca+super%282%2B%29+CHANNEL+ANTAGONIST+LERCANIDIPINE+IN+HUMAN+CARDIOVASCULAR+TISSUE&rft.jtitle=Clinical+and+experimental+pharmacology+%26+physiology&rft.au=Brixius%2C+Klara&rft.au=Gross%2C+Thomas&rft.au=Tossios%2C+Paschalios&rft.au=Geissler%2C+Hans-Joachim&rft.date=2005-09-01&rft.issn=0305-1870&rft.eissn=1440-1681&rft.volume=32&rft.issue=9&rft.spage=708&rft.epage=713&rft_id=info:doi/10.1111%2Fj.1440-1681.2005.04265.x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1870&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1870&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1870&client=summon |